CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION

Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KEREKES, Angela, Dawn, BRANCA, Danila, RICARDO, Alonso, INGENITO, Raffaele, GILBERT, Eric, J, HA, Sookhee, Nicole, YOUM, Hyewon, STRINGER, Joseph, R, CONTE, Immacolata, SANTOPRETE, Alessia, BIANCHI, Elisabetta, COSTANTINI, Willy, COLARUSSO, Stefania, BOYER, Nicolas, Cedric, XIONG, Yusheng, TUCKER, Thomas, Joseph, LAPLACA, Derek, M, WU, Chengwei, COSTANTE, Roberto, EMBREY, Mark, W, SHAHRIPOUR, Aurash
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.